B W Kuiper1, S Graybill2, J M Tate2, N Kaufman3, D Bersabe4. 1. Department of Internal Medicine Residency, SAUSHEC, Brooke Army Medical Center, Joint Base San Antonio, Fort Sam Houston, San Antonio, TX, USA. brandon.w.kuiper.mil@mail.mil. 2. Department of Endocrinology, SAUSHEC, Brooke Army Medical Center, Joint Base San Antonio, Fort Sam Houston, San Antonio, TX, USA. 3. Department of Internal Medicine Residency, SAUSHEC, Brooke Army Medical Center, Joint Base San Antonio, Fort Sam Houston, San Antonio, TX, USA. 4. Department of Internal Medicine, Wilford Hall Ambulatory Surgical Center, Joint Base San Antonio, Lackland Air Force Base, San Antonio, TX, USA.
Abstract
Osteoporotic hip fractures can be life changing and can increase mortality. Treatment of osteoporosis following hip fracture is often delayed. We began offering osteoporosis medication during hospitalization for hip fracture, dramatically increasing the number of patients meeting standard of care. INTRODUCTION: Osteoporotic hip fracture is a debilitating condition with major morbidity and mortality implications. Osteoporosis medication given within 90 days of hip fracture improves mortality and reduces risk of future fractures. The aim of this project was to improve rates of timely osteoporosis treatment following fragility hip fracture. METHODS: This was a two-step intervention utilizing the Plan-Do-Study-Act cycle, beginning with resident-focused education in cycle 1. In cycle 2, we offered osteoporosis medication to inpatients for hip fracture with help from a new electronic order set. RESULTS: Prior to this intervention, 32% of patients received osteoporosis medication within 90 days of fragility hip fracture; this improved to 81% after intervention. CONCLUSIONS: Resident education and an electronic order set dramatically improved the percentage of patients meeting standard of care with osteoporosis pharmacotherapy following fragility fracture.
Osteoporotic hip fractures can be life changing and can increase mortality. Treatment of osteoporosis following hip fracture is often delayed. We began offering osteoporosis medication during hospitalization for hip fracture, dramatically increasing the number of patients meeting standard of care. INTRODUCTION:Osteoporotic hip fracture is a debilitating condition with major morbidity and mortality implications. Osteoporosis medication given within 90 days of hip fracture improves mortality and reduces risk of future fractures. The aim of this project was to improve rates of timely osteoporosis treatment following fragility hip fracture. METHODS: This was a two-step intervention utilizing the Plan-Do-Study-Act cycle, beginning with resident-focused education in cycle 1. In cycle 2, we offered osteoporosis medication to inpatients for hip fracture with help from a new electronic order set. RESULTS: Prior to this intervention, 32% of patients received osteoporosis medication within 90 days of fragility hip fracture; this improved to 81% after intervention. CONCLUSIONS: Resident education and an electronic order set dramatically improved the percentage of patients meeting standard of care with osteoporosis pharmacotherapy following fragility fracture.
Entities:
Keywords:
Denosumab; Fragility hip fracture; Zoledronate
Authors: B J Edwards; A D Bunta; J Anderson; A Bobb; A Hahr; K J O'Leary; A Agulnek; L Andruszyn; K A Cameron; M May; N H Kazmers; N Dillon; D W Baker; M V Williams Journal: Osteoporos Int Date: 2012-01-25 Impact factor: 4.507
Authors: Amir Qaseem; Mary Ann Forciea; Robert M McLean; Thomas D Denberg; Michael J Barry; Molly Cooke; Nick Fitterman; Russell P Harris; Linda L Humphrey; Devan Kansagara; Robert M McLean; Tanveer P Mir; Holger J Schünemann Journal: Ann Intern Med Date: 2017-05-09 Impact factor: 25.391
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Michael J Taylor; Chris McNicholas; Chris Nicolay; Ara Darzi; Derek Bell; Julie E Reed Journal: BMJ Qual Saf Date: 2013-09-11 Impact factor: 7.035
Authors: H Spechbach; I Fabreguet; E Saule; M Hars; J Stirnemann; S Ferrari; R Rizzoli; T Chevalley Journal: Osteoporos Int Date: 2019-02-28 Impact factor: 4.507
Authors: Zeeshan Sheikh; Gang Chen; Faik Al-Jaf; Marion Thévenin; Kate Banks; Michael Glogauer; Robert N Young; Marc D Grynpas Journal: JBMR Plus Date: 2019-11-09
Authors: D González-Quevedo; V Pérez-Del-Río; D Moriel-Garceso; N Fernández-Arroyabe; G García-Meléndez; M Montañez-Ruiz; M Bravo-Bardají; D García-de-Quevedo; I Tamimi Journal: Osteoporos Int Date: 2022-03-31 Impact factor: 5.071
Authors: K E Åkesson; K Ganda; C Deignan; M K Oates; A Volpert; K Brooks; D Lee; D R Dirschl; A J Singer Journal: Osteoporos Int Date: 2022-03-24 Impact factor: 5.071